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The production of cytotoxic T cells with speciﬁcity for cancer cells is a rapidly evolving branch of cancer therapeutics. A variety
of approaches aim to amplify anti-tumour cytotoxic T cell responses using puriﬁed peptides, tumour cell lysates or
recombinant HLA/peptide complexes in differing antigen presenting systems. Using a two-step biotin-streptavidin antibody
targeting system, recombinant HLA-class I/peptide complexes were attached to the surface of B cells via the anti-CD20 B9E9-
scFvSA antibody-streptavidin fusion protein. Flow cytometry with a conformation dependant monoclonal antibody to HLA
class I indicated that targeted HLA-class I/peptide complexes remain on the surface of B cells in culture for periods in excess
of 72 h. PBMCs were stimulated in vitro for 8–14 days using the autologous B cells as antigen presenting cells. Following a
single cycle of stimulation speciﬁc cytotoxic T cell responses to targeted HLA-A2 complexes containing the M1, BMLF1 and
Melan A peptides could be demonstrated by tetramer staining and Cr release assays. With the HLA-A2/BMLF1 complex up
to 2.99% of CD8+ve cells were tetramer positive producing 20% lysis (E:T 10:1) of CIR-A2 target cells in an in vitro
cytotoxicity assay compared to baseline levels of 0.09% tetramer +ve and 2% lysis in the unstimulated population. PBMCs
from a healthy donor treated with two cycles of stimulations with targeted HLA-A2/Melan A complexes, demonstrated
expansion of the melanA tetramer +ve population from 0.03% to 1.4% producing 15% lysis of Melan A pulsed target cells.
With further consideration to the key variables of HLA/peptide complex density, the ratio of stimulator to effector cells and
optimum cytokine support, this system should offer an easy and effective method for the in vitro ampliﬁcation of speciﬁc
cytotoxic T cell responses and warrants development for the in vivo induction of cytotoxic T cell responses in cancer therapy.
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A central aim of cancer immunotherapy is the induction of effec-
tive cytotoxic T cell (CTL) activity that recognises HLA class I/
peptide complexes that are either speciﬁc to or over-represented
on tumour cells (Rosenberg, 1996). There is increasing evidence
that low levels of CTLs speciﬁc for ‘tumour’ peptides are present
in a number of malignancies (Pittet et al, 1999), however the
magnitude of these pre-existing responses frequently appears to
be insufﬁcient for effective in vivo activity.
The interaction between the HLA class I/peptide complex and the
T cells antigen receptor is the ﬁnal pathway in the expansion of CD8
+ve CTLs. A range of approaches aim to reach this interaction,
starting with either deﬁned tumour associated peptide or more
complex cellular based preparations. These methods include vacci-
nation with peptides (Rosenberg et al, 1998), naked DNA
(Mincheff et al, 2000) or irradiated tumour cells (Chan and Morton,
1998), these systems rely on processing and presentation by native
antigen presenting cells (APCs). Alternatively ex vivo expanded
dendritic cells can be used either with peptide pulsing (Hsu et al,
1996; Brossart et al, 2000), loading with tumour lysate (Nestle et
al, 1999) or transfected with genes encoding tumour proteins
(Wang et al, 2000a). Recombinant HLA-class I/peptide complexes
either immobilised on beads (Lone et al, 1998; Tham et al, 2001),
incorporated into antibody based fusion proteins (Cullen et al,
1999), or as recombinant MHC tetramers (Wang et al, 2000b) have
also produced effective CTL responses both in vitro and in pre-clin-
ical models. Dendritic cells are the most effective APCs but are
present in low numbers in vivo and are difﬁcult to culture, in
contrast B cells are present in large numbers, are simple to manip-
ulate in vitro and have been demonstrated to act effectively as APCs
inducing speciﬁc CTL responses in vivo (Gajewski et al, 2001).
Previously it has been demonstrated that HLA class I/viral peptide
complexes targeted to B cells via an antibody delivery system can
serve as effective targets for the lytic action of anti-viral CTLs (Ogg
et al, 2000; Savage et al, 2002). In this current study we have used a
similar system to investigate if the two-step antibody delivery system
(see Figure 1) is able to produce the speciﬁc expansion of CTLs of
chosen speciﬁcities from unselected populations of PBMCs.
MATERIALS AND METHODS
Antibodies
The B9E9 scFvSA fusion protein contains the single-chain variable
region of the murine IgG2a anti-CD20 murine antibody B9E9 fused
to the genomic streptavidin of Streptomyces avidinii. The protein is
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meric subunits (43400 Daltons) that spontaneously fold into soluble
tetramers with a molecular weight of 173600 Daltons. The four anti-
gen-binding and biotin-binding sites of the fusion protein retain the
functional capabilities of the parent molecules (Schultz et al, 2000).
The FITC conjugated monoclonal antibodies used in ﬂow cytometry
were anti-MHC class I (W6/32) (Cymbus Biotechnology, Harrow,
UK), anti-CD19, anti-CD80 and anti-CD86 (Dako, Ely, UK).
Cells
The CIR-A2 (Storkus et al, 1989) and Daudi (Klein et al, 1968) cell
lines were grown in RPMI + 10% FCS supplemented with Penicil-
lin and Streptomycin in a 378C incubator with 5% CO2.
PBMCs were isolated from healthy volunteers and melanoma
patients previously documented to be HLA-A2 +ve. Approximately
30 mls of venous blood was obtained by venepuncture and unfrac-
tionated PBMCs were obtained by differential centrifugation using
Histopaque (Sigma, Poole, UK).
HLA-A2/peptide complex monomers and tetramers
Recombinant HLA-A2 class I molecules were obtained from
ProImmune Ltd (Oxford Science Park, Oxford, UK). In brief,
recombinant HLA-A2 heavy chain and beta-2 microglobulin were
produced in E. coli. The functional HLA class I/peptide complex
were produced by refolding around the peptide of choice and then
biotinylation via the Bir A site on the HLA heavy chain (Garboczi
et al, 1992; Altman et al, 1996). The peptides used in these experi-
ments were Inﬂuenza virus M1 peptide GILGFVFTL (Gotch et al,
1987), Epstein-Barr virus (EBV) BMLF1 peptide GLCTLVAML
(Steven et al, 1997) and the modiﬁed melanoma associated Melan
A peptide ELAGIGILTV (Valmori et al, 1998). The PE conjugated
ﬂuorescent HLA-A2/peptide tetramers of the same speciﬁcities used
for ﬂow cytometric analysis were also obtained from ProImmune.
Targeting of B9E9 scFvSA and HLA-A2/peptide complexes
to HLA class I -ve B cells
HLA class I -ve Daudi cells were used to investigate the binding of
the HLA-A2/class I peptide complexes via the B9E9 scFvSA. Cells
were washed in PBS and incubated with B9E9 scFvSA diluted in
PBS at 10 ug ml
71 for 1 h at RT. After washing the cells were
incubated with either biotinylated HLA-A2/M1 peptide complexes
at 0.5 mgm l
71 or PBS alone for 30 min at RT. After further wash-
ing the two groups of cells were resuspended in RPMI + 10% FCS
and grown at 378C in a 5% CO2 atmosphere. At various time
points parallel samples of cells were removed, washed and incu-
bated for 30 min at RT with FITC conjugated W6/32, after
washing the cells were analysed by ﬂow cytometry.
The effects of B9E9 scFvSA binding on the expression of
co-stimulatory molecules in PBMC B cells
PBMCs prepared by differential centrifugation were incubated with
B9E9 scFvSA (10 mgm l
71), IL-7 (10 ng ml
71), B9E9 scFvSA and
IL-7 or PBS alone for 1 h at RT. After washing the cells were
placed into tissue culture media and returned to culture at 378C.
Samples were removed and double stained with PE conjugated
anti-CD19 and either FITC conjugated anti-CD80 or anti-CD86
and analysed on a Becton Dickinson FACScan using FACScomp
software.
In vitro immunisation protocol
PBMCs were incubated with the B9E9 scFvSA (10 mgm l
71)
diluted in PBS for 1 h at RT. After washing cells were incubated
with the biotinylated HLA class I/peptide complex (0.5 mgm l
71
in PBS) for 30 min at RT. Various controls, omitting the B9E9
scFvSA or the HLA class I/peptide complex were also performed.
After washing, cells were placed into 24-well plates at 3610
6 cells
per well and cultured in RPMI with 10% human AB serum. IL-7
(R and D Systems, Minneapolis, MN, USA) was added on day 1
at 10 ng ml
71 and IL-2 (Chiron, Hareﬁeld, UK) was added at
10 U ml
71 on day 4 and every further 3 days following the method
described by Lalvani et al (1997). In the experiments with a second
stimulation cycle further PBMCs were obtained and treated as
above. These new cells were then mixed with the existing culture
at a 1:2 ratio and the culture continued for a further 8 days.
Flow cytometry and tetramer analysis
To stain CD8 +ve cells from the PBMC culture approximately
1610
6 cells were washed in PBS, resuspended and incubated with
tetramer solution for 30 min at 378C followed by FITC conjugated
anti-CD8 for 20 min at 48C. After incubation the cells were
washed, resuspended in PBS and analysed by dual colour ﬂow
cytometry. The results of ﬂow cytometry analysis of dual stained
PBMCs are shown with anti-CD8 (Y axis) and HLA-A2/M1 tetra-
mers (X axis). Percentage ﬁgures relate to the number of tetramer
positive CD8 +ve cells from the total CD8 +ve population.
Chromium release assay
Daudi or CIR-A2 cells were labelled with 2 uCi/uL of
51Cr (Amer-
sham Pharmacia, UK) for 1 h at 378C then washed. Daudi cells
were sequentially coated with B9E9 scFvSA and HLA-A2/M1
complexes following the method above whilst CIR-A2 cells were
pulsed with the peptide of choice at a concentration of 10 uM
for 1 h at 378C. The target cells were plated at 3000 cells per well
in U bottomed 96-well plates. PBMCs, media or 5% Triton X-100
were added to a ﬁnal volume of 200 ml. Plates were incubated for
4 h at 378C in a 5% CO2 atmosphere and 50 ml of supernatant was
collected and added to 150 ml of scintillant. The speciﬁc lysis was
calculated as:
% lysis 
experimental c:p:m:-spontaneous c:p:m:  100
maximum c:p:m:-spontaneous c:p:m:
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Figure 1 Schematic representation of the two-step targeting system
delivering HLA-class I peptide complexes to the surface of B cells. Step 1
is the delivery of the anti-CD20 B9E9 sfvScSA fusion protein. Step 2 the
delivery of recombinant biotinylated HLA class I peptide. These steps are
followed by the selective proliferation of peptide speciﬁc CTLs.
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media alone, the maximum release was measured from the cells
incubated in 5% Triton.
RESULTS
Sequential analysis of the binding of biotinylated HLA-A2/
M1 complexes to Daudi B-cell lymphoma cells via B9E9
scFvSA
The time course of the retention of the targeted HLA-A2/M1
complexes retention the HLA class I -ve Daudi cells is
demonstrated in the sequential ﬂow cytometry analyses in
Figure 2. An increased ﬂuorescence signal is demonstrated
in the targeted cells which decreases with time. However a
positive signal is still present at 72 h and it is probable that
HLA class I/peptide complexes persist at functional levels
beyond this time.
Effects of B9E9 scFvSA binding on the expression of
co-stimulatory molecules in PBMC B cells
Figure 3 demonstrates that the addition of B9E9 scFvSA has no
detectable effect on the expression of CD80 or CD86 on the B cells
within the PBMC population. The results show the ﬂow cytometry
results for CD19 +ve cells at 3 h and 24 h. PBMCs treated with IL-
7 alone or the combination of B9E9 scFvSA and IL-7 also demon-
strated no change in the levels of expression of CD80 and CD86
(data not shown).
Induction of CTL activity with targeted HLA class I/peptide
complexes
The ability of the antibody targeted complexes to stimulate
CTL expansion was initially examined with the HLA-A2/M1
combination. In Figure 4 the tetramer analysis of the
CD8+ve/HLA-A2/M1 positive cells within the unstimulated
PBMCs (1), PBMCs targeted with the B9E9 scFvSA (2), and
PBMCs exposed to free soluble HLA-A2/M1 complexes at
0.1 ng ml
71 (3) demonstrate values of 0.06% to 0.22%. In
contrast the PBMCs targeted with the B9E9 scFvSA and
HLA-A2/M1 complexes (4) demonstrated 2.33% tetramer posi-
tive CD8+ve cells. Using the unfractionated PBMCs at E:T
10:1, a 4 h Cr release assay, using HLA-A2/M1 coated Daudi
cells as target cells, demonstrated a maximum of 10% lysis
from the three control experiments but 24% from the PBMCs
stimulated with HLA-A2/M1 complexes attached via the B9E9
scFvSA fusion protein.
Induced CTL responses are speciﬁc for the targeted
complex
To conﬁrm the speciﬁcity of CTL expansion, PBMCs were targeted
with either B9E9 scFvSA alone (A) or B9E9 scFvSA and HLA-A2/
BMLF1 complexes (B).
In Figure 5 the tetramer analysis of the PBMCs targeted with
B9E9 scFvSA alone demonstrates background staining of 0.04%
with HLA-A2/M1 and 0.09% with HLA-A2/BMLF1. In the Cr
release assay against CIR-A2 cells either native or pulsed with
M1 or BMLF1 peptide the PBMCs showed no signiﬁcant activity.
In contrast PBMCs targeted with the HLA-A2/BMLF1 complexes
demonstrate 2.99% staining with the HLA-A2/BMLF1 tetramer
but with only a background staining level of 0.01% with the
HLA-A2/M1 tetramer. These cells produced 20% lysis of the
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Figure 2 Time course analysis of HLA-A2/M1 complexes immobilised on the surface of HLA-class 1 7ve Daudi cells via B9E9 sfvScSA. Complexes are
detected via the binding of W6/32 which binds conformationally correct HLA-class I. Daudi cells targeted with B9E9 sfvScSA alone are shown in grey, in
black are Daudi cells targeted with B9E9 sfvScSA and HLA-A2/M1.
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Figure 3 Sequential ﬂow cytometry analysis of expression of CD80 and
CD86 on CD19 +ve B cells within the PBMC population. The unstimulated
controls are shown on the narrow trace, the experimental results from
PBMCs targeted with the B9E9 sfvScSA are shown in bold.
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on native or M1 pulsed cells.
CTL responses to a single cycle of stimulation with
HLA-A2/peptide complexes in healthy donors and
melanoma patients
The numerical values of the tetramer results from PBMCs from a
series of healthy donors and melanoma patients are demonstrated
in Table 1. In response to stimulation with targeted HLA-A2/M1
complexes a greater than ﬁve-fold increase in the number of tetra-
mer +ve cells are seen in six of the eight volunteers and one of two
melanoma patients. From the HLA-A2/BMLF1 stimulated cells one
of the ﬁve volunteers showed a greater than ﬁve-fold increase with
two others showing apparent increases. In response to targeted
HLA-A2/Melan A complexes greater than three-fold increases in
tetramer positive cells were seen in three of four volunteers and
in one of the melanoma patients.
CTL responses to HLA-A2/M1 and Melan A can be
enhanced by a repeated stimulation
Figure 6 demonstrates the CTL responses produced by two rounds
of in vitro stimulation using the same HLA-A2/peptide complex.
The 4 h Cr release assay (E:T 20:1) demonstrates that PBMCs
stimulated with targeted HLA-A2/M1 complexes on both day 1
and day 8 produce 14% lysis of the CIR-A2 M1 pulsed cells
compared with 3% lysis of native and 6% lysis of CIR-A2 melanA
pulsed cells. The increase in HLA-A2/M1 speciﬁc CTLs is shown in
the tetramer series with 0.09% from unstimulated cells (1A), 0.68%
after one cycle (1B) and 2.32% after two cycles (1C). In this donor
similar results were seen with responses to melan A with a 15%
lysis of CIR-A2 cells pulsed with the Melan A peptide and increases
in tetramer staining from a background of 0.06%, 0.16% after one
cycle and 1.40% after two cycles. In this experiment cells subject to
one cycle of stimulation did not produce detectable activity in the
Cr release assay (data not shown).
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Figure 4 FACs and Cr release assay results from PBMCs stimulated with
targeted HLA-A2/M1 complexes. Tetramer results demonstrate staining
with anti-CD8 and HLA-A2/M1 tetramer. The Cr release assay demon-
strates activity against Daudi cells bearing HLA-A2/M1 complexes. Stimula-
tion protocols:1/ PBMCs alone, 2/ PBMCs + B9E9 sfvScSA, 3/ PBMCs +
free HLA-A2/BMLF1, 4/ PBMCs + B9E9 sfvScSA + HLA-A2/BMLF1.
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Figure 5 FACs and Cr release assay results from PBMCs stimulated with
either (A) B9E9 sfvScSA alone or (B) B9E9 sfvScSA and targeted HLA-A2/
BMLF1 complexes. Tetramer staining results are shown for both HLA-A2/
M1 and HLA-A2/BMLF1. The Cr release assay demonstrates PBMC at E:T
10:1 against native/M1/BMLF1 peptide pulsed CIR-A2 target cells.
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Figure 6 FACs and Cr release assay results from PBMCs stimulated
twice with either (1) targeted HLA-A2/M1 complexes or (2) targeted
HLA-A2/Melan A complexes. Tetramer results are (A) unstimulated, (B)
targeted once and (C) targeted twice. The Cr release assay with twice tar-
geted PBMCs shows the activity against native and peptide pulsed CIR-A2
cells at E:T 20:1.
Table 1 Frequencies of tetramer+ve CTLs to HLA-A2/M1, BMLF1 and
Melan-A in healthy donors or *melanoma patients before and after 1
round of in vitro stimulation
HLA-A2+M1 +BMLF1 +MelanA
Donor Pre 1 Cycle Pre 1 Cycle Pre 1 Cycle
RT 0.21 1.08 0.54 0.63 – –
SL 0.04 0.41 0.28 0.26 – –
JaR 0.00 0.32 0.30 0.85 – –
LOB 0.00 0.01 0.08 0.31 – –
LL 0.09 2.20 0.09 2.99 0.06 0.26
CJ 0.16 0.57 – – 0.04 0.13
JuR 0.07 0.52 – – 0.09 0.08
DV 0.07 0.80 – – 0.03 0.14
BB* 0.00 0.22 – – 0.41 1.33
DB* 0.36 0.91 – – 0.42 0.21
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The induction of an effective immune response against malignant
cells has been an aim of cancer research for over a century. With
the increasing understanding of how the immune system can
differentiate between normal and malignant cells a number of
cancer vaccine approaches have been examined. To date many of
these have centred on the use of undeﬁned antigens via tumour cell
lysates or irradiated cells. However with the identiﬁcation of a
number of potential tumour peptide epitopes (Boon and van der
Bruggen, 1996; Vonderheide et al, 1999) and the ease of manufac-
ture of recombinant HLA class I peptide complexes (Garboczi et al,
1992) it is now feasible to consider highly speciﬁc approaches to
cancer vaccine strategies.
Puriﬁed immobilised HLA class I/peptide complexes have been
shown to interact and stimulate CTLs when attached to tissue
culture plates (Kane et al, 1989), chemically attached to cells
(Anjuere et al, 1995; Walter et al, 1997) or when coated onto beads
(Motta et al, 1998). More recently antibody targeted HLA class I/
peptide complexes have been demonstrated to successfully interact
with CTLs to permit lysis of targeted cells in vitro (Ogg et al, 2000;
Robert et al, 2000).
The ability of B cells targeted with HLA class I/peptide
complexes to induce CTL responses is clearly shown in Figures
4, 5 and 6. In vitro CTL responses demonstrated by tetramer and
Cr release assays were obtained when the HLA class I/peptide
complexes were targeted to PBMCs pre-treated with the B9E9
scFvSA fusion protein. In contrast free HLA class I/peptide
complexes produced no apparent responses indicating the require-
ment for either multimerisation or immobilisation of HLA class I/
peptide complexes for effective CTL stimulation as previously
described (Abastado et al, 1995; Motta et al, 1998). The speciﬁcity
of the CTL expansion is conﬁrmed by the results shown in Figure 5
where increases in tetramer staining and lysis of peptide pulsed
target cells was only seen in response to stimulation with that
speciﬁc HLA/peptide complex. The ability of this system to further
increase responses by repeated stimulation is shown in the tetramer
stain results of Figure 6. Here the frequencies of CTLs reactive with
HLA-A2/M1 increase from 0.09% to 2.32% after a second cycle. In
this donor the MelanA results of 0.06% and 1.4% show as similar
pattern, with positive Cr release assays after two cycles.
The efﬁciency of CTL induction has previously been shown to
be related to the stability and length of expression of the HLA
class-I complex on the surface of antigen presenting cells (Van
der Burg et al, 1996; Valmori et al, 1998; Micheletti et al, 1999).
In this antibody targeting system we have aimed to optimise the
time course for expression of the HLA class I complexes, by using
complexes with documented long half lives and a high afﬁnity
binding system to a non-internalising B cell marker. The ability
of these complexes to persist in a conformationally correct form
for at least 72 h on the surface of the B cells is demonstrated in
Figure 2. It is probable that functionally active levels of complexes
remain on the surface of the B cells for a longer period as we have
previously shown that CTLs can interact efﬁciently with B cells
with levels of targeted HLA below that detectable by ﬂow cytome-
try (Savage et al, 2002).
The data in Figure 3 demonstrates that binding of the B9E9
scFvSA to the B cells within the PBMCs either alone or in conjunc-
tion with IL-7 had no effect on the expression of B80 and B86.
Whilst the enhanced expression of co-stimulatory molecules gener-
ally increases CTL responses, it has previously been demonstrated
that effective CTL can be produced without accessory molecule
expression, particularly when high epitope densities are used
(Wang et al, 2000b).
At present there has been only limited optimisation of this in
vitro stimulation protocol and it is apparent from Table 1 that
there is considerable variation in the level of CTL responses
produced from different individuals. However the ability to
produce CTL responses to viral peptides in the majority of donors
from a single round of in vitro immunisation compares favourably
with in vitro results from both peptide pulsing (Lalvani et al,
1997) and dendritic cells (Larsson et al, 2000). Further work is
in progress to optimise the system, however it was observed in
the experimental cultures using targeted HLA class I/peptide
complexes there was signiﬁcant inhibition of proliferation
compared to those targeted with the B9E9 fusion protein alone
(data not shown). It is possible that the effect of the supra-
physiological stimulation prevents expansion of the speciﬁc CTL
population either via a direct apoptotic action or the result of
high levels of cytokine production within the closed system.
Studies in mice have shown that increased antigenic density can
result in higher CTL activity but produces a signiﬁcant reduction
at very high densities (Wherry et al, 1999). Similarly in human
systems the presence of supra-optimal levels of HLA class I
complexes can lead to apoptosis rather than expansion of stimu-
lated CD8 +ve CTLs (Alexander-Miller et al, 1998). As CD20 is
present at approximately 50000 copies per B cell (Marti et al,
1992), saturated binding of HLA class I/peptide complexes could
result in 50000–200000 copies of a single peptide/HLA class I
combination per cell. This is signiﬁcantly higher than produced
by peptide pulsing which results in peptide placement in 5000
copies of an individual HLA allele (Delon et al, 1998) out of a
total allele number of 10
5 per B cell (Kageyama et al, 1995;
McCune et al, 1975). Additionally the stability of the recombinant
complexes appears to be greater than those produced by peptide
pulsing which have an average half life of only 2.5–4 h (Wataya
et al, 2001) which may further increase the strength and duration
of T cell activation.
The B9E9 scFvSA fusion protein is currently in clinical trials for
the treatment of B cell lymphoma using radiolabelled biotin as the
effector function. The ease of administration, lack of toxicity and
option for repeated doses suggest that using this molecule in a
vaccine strategy should be feasible. To date recombinant HLA class
I molecules are yet to be administered to cancer patients, however
as endogenous HLA class I molecules circulate in health and in
increased levels in a number of illnesses (McMillan et al, 1997) they
are unlikely to have any major direct toxicity.
In this preliminary work we have focused on stimulation with a
single HLA class I/peptide complex, however the ability to make
these recombinant molecules of any chosen HLA class I/peptide
combination should allow for vaccination with a range of
complexes either sequentially or concurrently. As the stability of
the HLA class I/peptide complexes appears to vary considerably
with the identity of the peptide (Valmori et al, 1998) and stability
is closely linked to the immunogenicity of a chosen HLA class I/
peptide complex, it is possible that recombinant molecules that
incorporate the peptide/HLA heavy chain/beta-2-microglobulin
into fusion proteins may offer potential beneﬁts.
The initial clinical studies will use PBMCs targeted with
complexes ex vivo, which will allow accurate administration of
designated numbers of targeted cells at the optimum epitope
density. This approach should also minimise the potential immu-
nogenicity of the streptavidin in the fusion protein and the
potential risk of uncontrolled CTL expansion that could occur with
intravenous HLA classI/complex administration that would result
in the targeting of the total B cell population.
The ability of antibody targeted HLA class I/peptide complexes
to speciﬁcally induce the expansion of CTLs to a single speciﬁcity
should prove useful for in vitro studies analysing the endogenous
CTL response or the effects of other in vivo procedures. Potentially
this system could also be used for the ex vivo production of CTLs
for the adoptive immunotherapy of cancer and other diseases.
However a vaccination procedure based on targeting HLA class
I/peptide complexes to B cells in vivo via the antibody delivery
system could offer signiﬁcant advances in both the applicability
and effectiveness of cancer vaccines.
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